2020
DOI: 10.21203/rs.3.rs-122656/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

How to Design a Registry for Undiagnosed Patients in the Framework of Rare Disease Diagnosis – Suggestions on Software, Data Set and Coding System

Abstract: Background: About 30 million people in the EU and USA, respectively, suffer from a rare disease. Driven by European legislative requirements, national strategies for the improvement of care in rare diseases are being developed. To improve timely and correct diagnosis for patients with rare diseases, the development of a registry for undiagnosed patients was recommended by the German National Action Plan. In this paper we focus on the question on how such a registry for undiagnosed patients can be built and whi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…Approximately 7000 kinds of rare diseases (RDs) have been genetically identi ed to date, and many undiagnosed diseases are now known rare diseases that require established testing [1,2]. Unlike prior undiagnosed disease programs that focused on the diagnosis itself, current studies emphasize determining disease mechanisms and searching for therapeutic targets using various tools, such as data sharing, model organisms and supporting experiments, as well as identifying ultrarare diseases [3][4][5][6]. However, the clinical demand for RDs still exists.…”
Section: Introductionmentioning
confidence: 99%
“…Approximately 7000 kinds of rare diseases (RDs) have been genetically identi ed to date, and many undiagnosed diseases are now known rare diseases that require established testing [1,2]. Unlike prior undiagnosed disease programs that focused on the diagnosis itself, current studies emphasize determining disease mechanisms and searching for therapeutic targets using various tools, such as data sharing, model organisms and supporting experiments, as well as identifying ultrarare diseases [3][4][5][6]. However, the clinical demand for RDs still exists.…”
Section: Introductionmentioning
confidence: 99%